Facebook
Twitter
LinkedIn
ForwardPart 4: Balancing Safety and Efficacy with Novel Schizophrenia Treatments
Balancing symptoms and side effects is difficult when treating patients with schizophrenia. New approaches to treatment and new therapies in the pipeline offer hope for this difficult-to-treat mental health disorder.
Category
- Schizophrenia/ Schizoaffective Disorders
Format
- Video
- Self-study / Enduring
Credits
- 0.50 AMA PRA Category 1 Credit™
- 0.50 Participation
Tardive Dyskinesia: Subtle Symptoms and the Huge Impact of Early Recognition and Intervention
Clinicians should screen regularly for signs and symptoms of tardive dyskinesia and educate patients and caregivers on what to look for and report, leading to earlier intervention and better quality of life.
Category
- Movement Disorders
- Psychotic Disorders
- Side Effects
- Tardive Dyskinesia
Format
- Self-study / Enduring
- Video
Credits
- 1.00 AMA PRA Category 1 Credit™
- 1.00 Participation
Episode 1: Why the Duration Until Onset of Antidepressant Matters
Pharmacology for MDD is limited by low efficacy, delayed response, and side effects. Research on the pathophysiology of the disease that includes the glutamatergic system and GABA signaling is ushering in a new era for rapidly acting antidepressants.
Category
- Depression
- Major Depressive Disorder
- Women’s Mental Health
Format
- Video
- Self-study / Enduring
Credits
- 0.50 AMA PRA Category 1 Credit™
- 0.50 Participation
Episode 2: Update on Rapid-Onset Therapies for Major Depressive Disorder
The new fast-acting antidepressants esketamine, an NMDA receptor antagonist, and positive allosteric modulators of GABAergic neurotransmission brexanolone and zuranolone have created an important and exciting paradigm shift in the treatment of depression.
Category
- Depression
- Major Depressive Disorder
- Women’s Mental Health
Format
- Video
- Self-study / Enduring
Credits
- 0.50 AMA PRA Category 1 Credit™
- 0.50 Participation
Therapeutic Advances for Epileptic Seizure Rescue
Neurologists and other clinicians can improve care by identifying individuals who are susceptible to seizure clusters and educating them on rescue therapies and medications.
Category
- Epilepsy
Format
- Video
- Self-study / Enduring
Credits
- 0.50 AMA PRA Category 1 Credit™
- 0.50 Participation
Parkinson's Disease Psychosis: Review of Neuropsychiatric Complications
An average of 35% of patients diagnosed with Parkinson’s disease experience Parkinson’s psychosis. Recognition and diagnosis of this nonmotor manifestation is critical in choosing the best treatment strategy and managing these symptoms.
Category
- Parkinson Disease
Format
- Video
- Self-study / Enduring
Credits
- 0.50 AMA PRA Category 1 Credit™
- 0.50 Participation
Seizure Clusters in the Real World: The Call to Arms
Treatment standards for neurologists and other clinicians caring for patients with epilepsy with emphasis on understanding epilepsy epidemiology, SUDEP and ILAE Classification updates, and therapeutic strategies.
Category
- Epilepsy
Format
- Video
- Self-study / Enduring
Credits
- 0.50 AMA PRA Category 1 Credit™
- 0.50 Participation
Improving Clinician Awareness of Rett Syndrome and Optimizing Management of Care Across the Patient Lifespan
Because of the multiple comorbidities associated with Rett syndrome, clinicians are advised to incorporate clinical guidelines that suggest implementing therapeutics with a multidisciplinary approach and with an eye toward new and emerging therapies.
Category
- Rett Syndrome
- Child and Adolescent Psychiatry
- Movement Disorders
- Neurology
Format
- Video
- Self-study / Enduring
Credits
- 1.00 AMA PRA Category 1 Credit™
- 1.00 Participation
An Individualized Approach to PAH Therapy Based on Clinical Data, Goal-Directed Therapy, and Risk Stratification
Pulmonary arterial hypertension requires risk stratification to develop goal-directed treatment plans, including combination therapy targeting multiple pathways.
Category
- Cardiology
- Comorbidity
- Education
- Integrated Care
- Medical Conditions
- Pulmonary Disease
Format
- Video
- Self-study / Enduring
Credits
- 1.00 AMA PRA Category 1 Credit™
- 1.00 Participation
Translating Clinical Trial Data into Real-World Practice: Examining CKD Screening and Three Patient Case Profiles
Regular screening of UACR and adding finerenone to SGLT2 inhibitors can greatly impact T2D at risk for CKD. Join faculty as they discuss three patient cases.
Category
- Renal Disease
- Adherence
- Cardiology
- Comorbidity
- Diagnostic Tools
- Education
- Medical Conditions
- Primary Care
- Side Effects
- Weight
Format
- Video
- Self-study / Enduring
Credits
- 1.00 AMA PRA Category 1 Credit™
- 1.00 Participation